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Cardiovascular comorbidities remain to be one of the most prominent risk factors for a poor clinical outcome of se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection. In addition to the respiratory tract, the myocardium 
is also often affected by SARS-CoV-2.1 Although the virus has 
been detected in myocardial tissue, it remains unclear if car-
diac pathologies are caused directly by the virus or by other, 
for example, immunologic factors.
Human ACE2 (angiotensin-converting enzyme 2) is rec-
ognized as the main receptor for SARS-CoV-2. It is expressed 
in many organs, including the respiratory tract, kidney, and 
heart. Thus, some reports suggest that ACE2 play a role in 
cardiac SARS-CoV-2 infection.2,3 ACE2 is the rate-limiting 
enzyme in the degradation of the fibrogenic and proinflam-
matory AngII (angiotensin II) peptide and therefore a major 
player in the pathophysiology of heart disease. A recent single-
cell RNA sequencing study showed increased ACE2 expres-
sion in cardiomyocytes of a very small cohort of patients with 
aortic stenosis (AS) and with heart failure.3 To better under-
stand the pathophysiological circumstances in which ACE2 is 
upregulated in the heart on protein level, we took advantage of 
a well-established proteomic approach and compared prote-
omic characteristics of n=75 human myocardial samples from 
n=41 patients with severe AS, n=17 patients with severe mitral 
valve regurgitation, and n=17 controls. Myocardial samples 
were collected from the left ventricular septum during valve 
surgery and were frozen at −80 °C. Both patient groups had 
cardiac hypertrophy but no significant reduced left ventricular 
ejection fraction (Figure [A]). Controls were healthy organ 
donors without cardiovascular diseases but whose hearts 
could not be transplanted because of nonmedical reasons. 
Protein abundances were determined by label-free shot-gun 
mass spectrometry on a Thermo Orbitrap instrument and ana-
lyzed by MaxQuant with 1% false discovery rate. The study 
was approved by the local ethics committee.
In patients with AS, ACE2 protein was 4.76-fold upregulated 
compared with controls (adj. P<0.0001) and 4.04-fold compared 
with patients with mitral valve regurgitation (adj. P<0.001). In 
patients with mitral valve regurgitation, ACE2 abundance did 
not show any significant differences when compared with con-
trols (Figure [B]). To confirm the validity of these results, protein 
abundance was compared with available cardiac transcriptome 
data of 17 patients with AS and 6 controls from the same co-
hort. Likewise to the proteomic results, ACE2 was significantly 
(adj. P<0.05) upregulated in AS compared with controls (Figure 
[D]). Moreover, there was a significant correlation between 
ACE2 protein abundance and mRNA expression levels (R=0.6, 
P<0.01) suggesting a direct link between cardiac ACE2 tran-
scription levels and the amount of generated ACE2.
Furthermore, a logistic regression model (Pseudo-R2, 0.40; 
P<0.001, area under the curve [AUC] 0.89), adjusted for age, 
sex, antihypertensive medication revealed that allocation to the 
pressure-overloaded AS group (odds ratio, 44.2 [95% CI, 1.5–
1331.4]; P=0.029) was the most relevant factor for ACE2 pro-
tein levels exceeding the intergroup median. ACE-inhibition 
was another independent factor for ACE2 levels exceeding 
the inter-group median (odds ratio, 10.3 [95% CI ,1.2–91.6]; 
P=0.036) with 95% CIs above 1. Relevant effects were not 
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found for AngII receptor blockers (odds ratio, 2.3 [95% CI, 
0.3–21.4]; P=0.453). No relevant effects of age were found on 
quantitative ACE2 upregulation.
In addition to a relevant pressure gradient across the 
valve, patients with AS had higher blood pressures than mi-
tral valve regurgitation and controls. Whereas both effects 
remain difficult to distinguish, the pathophysiological reason 
for an increased ACE2 expression in pressure-overload hearts 
might be a compensatory mechanism that mediates the well 
described antihypertrophic and antifibrotic actions of ACE2 
in the heart.4 This assumption is further supported by the fact 
that the intensity of ACE2 abundance positively correlates 
with the pressure gradient in AS (Coefficient, 0.028 [95% CI, 
0.003–0.054]; P=0.029). Despite covering a large range of 
proteins, ACE abundance was below the detection limit and 
thus could not be quantified robustly. However, ACE mRNA 
was detected, and expression levels were nonsignificantly 
(adj. P=0.06) increased in AS compared with controls.
Although care should be taken when interpreting results 
in terms of causality because of the observational design of 
the present study, ACE-inhibition intake was another inde-
pendent factor for ACE2 levels exceeding the intergroup 
median (Figure [B]). Whether this fact is relevant in patients 
with SARS-CoV-2 is still speculative. Until now, there is no 
evidence that ACE-inhibition or AngII receptor blockers are 
associated with a more severe outcome in patients infected 
with SARS-CoV-2.5
In conclusion, the present study found evidence that ACE2 
is differently regulated in pressure- or volume-overload hearts 
because of valve disease. Further research is needed to investi-
gate whether other pressure load conditions such as arterial hy-
pertension also lead to increased ACE2 expression and whether 
such conditions can enhance ACE2 expression also in tissues of 
initial SARS CoV-2 infection, such as the upper airways.
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Figure.  Distinct ACE2 (angiotensin-converting enzyme 2) expression of the putative severe acute respiratory syndrome coronavirus 2 receptor in heart 
disease. A, Table with patients’ and controls’ characteristics. Difference between groups was tested by Welch t test (numerical) or χ2 test (categorical). 
Significant differences between the patients’ groups and controls are marked bold. ACE2 expression values from (B) protein measurements as log2 label-
free-quantification intensities (n=41 aortic stenosis [AS], 17 mitral valve regurgitation [MR], 17 control [CON]), and (C) RNA sequencing as log2 counts 
per million (n=17 AS, 6 CON). Individual values per patient are plotted as dots. Missing values are not shown but were down-shift imputed for statistical 
testing. D, Sample-wise derivation of cardiac ACE2 protein abundance from the median log2 expression value (set to 0). Each bar represents 1 sample, 
while annotation columns below denote selected baseline characteristics. Statistical analysis was performed using R including limmas moderated t test and 
Benjamini-Hochberg multiple testing correction. ARB indicates angiotensin II receptor blocker; and BMI, body mass index. Significance levels—ns: P>0.05, 
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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